The present disclosure provides multispecific (e.g., bispecific) antibodies that specifically bind to human GITR and/or human OX40 as well as compositions comprising such antibodies. In a specific aspect, the multispecific antibodies specifically bind to human GITR and OX40 and modulate GITR and/or OX40 activity, e.g., enhance, activate, or induce GITR and/or OX40 activity, or reduce, deactivate, or inhibit GITR and/or OX40 activity. The present disclosure also provides methods for treating disorders, such as cancer, by administering a multispecific antibody that specifically binds to human GITR and/or OX40 and modulates GITR and/or OX40 activity, e.g., enhances, activates, or induces GITR and/or OX40 activity. Also provided are methods for treating autoimmune or inflammatory diseases or disorders, by administering a multispecific antibody that specifically binds to human GITR and/or OX40 and modulates GITR and/or OX40 activity, e.g., reduces, deactivates, or inhibits GITR and/or OX40 activity.本發明提供特異性結合人類GITR及/或人類OX40之多特異性(例如雙特異性)抗體及包含該等抗體之組合物。在一個特定態樣中，該等多特異性抗體特異性結合人類GITR及OX40且調節GITR及/或OX40活性，例如增強、活化或誘導GITR及/或OX40活性、或降低、去活化或抑制GITR及/或OX40活性。本發明亦提供用於治療諸如癌症之病症的方法，該等方法係藉由投予多特異性抗體，該多特異性抗體特異性結合人類GITR及/或OX40且調節GITR及/或OX40活性，例如增強、活化或誘導GITR及/或OX40活性。本發明亦提供用於治療自體免疫或發炎性疾病或病症之方法，該等方法係藉由投予多特異性抗體，該多特異性抗體特異性結合人類GITR及/或OX40且調節GITR及/或OX40活性，例如降低、去活化或抑制GITR及/或OX40活性。
